Endocrinology Department, Cesar Milstein Hospital, 951 La Rioja St, 1221, Buenos Aires, Argentina.
Biochemistry Department, Cesar Milstein Hospital, 951 La Rioja St, 1221, Buenos Aires, Argentina.
J Endocrinol Invest. 2017 Dec;40(12):1303-1310. doi: 10.1007/s40618-017-0690-2. Epub 2017 May 22.
Overt hypothyroidism has adverse clinical consequences and might worsen prognosis in critically ill elderly patients. However, the difficult interpretation of thyroid function tests (TFT) due to non-thyroidal illness (NTI) has led to discouragement of screening for thyroid dysfunction. Our aim was to determine the prevalence of TFT compatible with hypothyroidism and to study its influence on mortality among hospitalized elderly patients.
In this prospective study we consecutively included all patients ≥60 years admitted by the Internal Medicine Department to the hospital ward (n = 451) of the Cesar Milstein Hospital in Buenos Aires, Argentina. TFT were done on day 1 and 8. Thyroid function categories were defined as overt and subclinical hypothyroidism, overt and subclinical hyperthyroidism, euthyroidism and NTI. Stage of chronic kidney disease (CKD), Adult Comorbidity Evaluation (ACE)-27, and intra-hospital mortality were recorded. The association between mortality and TFT categories was studied by Cox regression.
Out of 451 patients (77.0 ± 7.9 years, 54% females) 76% were categorized as NTI, 4% as overt hypothyroid, 10% as subclinical hypothyroid, 1% as subclinical hyperthyroid and 9% as euthyroid. Overt hypothyroid patients showed significantly higher mortality than the rest of the groups (25%, p < 0.05) while ACE-27 was similar among all of them (p = 0.658). In addition, patients within the overt hypothyroid category showed a higher mortality rate than NTI in a model adjusted by Stage 5-CKD, ACE-27, sex and age [HR 3.1 (1.14-8.41), p < 0.026].
Overt hypothyroidism during hospitalization was associated with elevated mortality. Further studies would reveal if TFT alterations compatible with hypothyroidism should be diagnosed/treated in hospitalized elderly patients.
显性甲状腺功能减退症有不良的临床后果,并可能使危重病老年患者的预后恶化。然而,由于非甲状腺疾病(NTI)导致甲状腺功能检测(TFT)难以解读,因此不鼓励对甲状腺功能障碍进行筛查。我们的目的是确定住院老年患者中符合甲状腺功能减退症的 TFT 患病率,并研究其对死亡率的影响。
在这项前瞻性研究中,我们连续纳入了所有因内科疾病入住阿根廷布宜诺斯艾利斯的 César Milstein 医院住院病房(n=451)的≥60 岁患者。TFT 在第 1 天和第 8 天进行。甲状腺功能分类为显性和亚临床甲状腺功能减退症、显性和亚临床甲状腺功能亢进症、甲状腺功能正常和非甲状腺疾病。记录慢性肾脏病(CKD)分期、成人合并症评估(ACE)-27 和院内死亡率。通过 Cox 回归研究死亡率与 TFT 分类之间的关系。
451 例患者中(77.0±7.9 岁,54%为女性),76%归类为非甲状腺疾病,4%为显性甲状腺功能减退症,10%为亚临床甲状腺功能减退症,1%为亚临床甲状腺功能亢进症,9%为甲状腺功能正常。与其他组相比,显性甲状腺功能减退症患者的死亡率明显更高(25%,p<0.05),而 ACE-27 在所有患者中相似(p=0.658)。此外,在调整了 5 期 CKD、ACE-27、性别和年龄的模型中,显性甲状腺功能减退症患者的死亡率高于非甲状腺疾病患者[HR 3.1(1.14-8.41),p<0.026]。
住院期间显性甲状腺功能减退症与死亡率升高有关。进一步的研究将揭示是否应在住院老年患者中诊断/治疗符合甲状腺功能减退症的 TFT 改变。